Who we are

The EUMCA is the authoritative voice for the medicinal cannabis industry sector, representing ethical European manufacturers and suppliers of pharmaceutical-grade cannabis products. Its membership is a multi-stakeholder network representing the interests of a wide range of organisations operating in the research and development, production and/or distribution of medical cannabis-based treatments.

The European Medicinal Cannabis Association (EUMCA) is the only not-for-profit European medicinal cannabis association, that is both registered and governed by the provisions of the Belgian Code des Sociétés et des Associations and registered on the European Commission Transparency Registry.
“The goal for the European Medicinal Cannabis Association is that we work with our membership, the European Union, and national member-state governments to develop evidence-based policies for high-quality cannabis treatments.”

Prof Trevor M Jones CBE FMedSci
PhD DSc Hon FRCP FBPhS FRSM FRSC FLSW

Professor Jones is an accomplished and distinguished scientist, policy expert and businessman who, in the course of his career, has made a central contribution to global health through his scientific research and development output. As Group R&D Director at The Wellcome Foundation Ltd he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. He was a Director of Allergan Inc. (USA), and Director General of the Association of the British Pharmaceutical Industry (ABPI).

Professor Jones served for 12 years as a member of the UK Government Regulatory Agency Medicines Commission and as Chairman of the UK Government Advisory Group on Genetics Research. Currently he is Director of the Life Sciences investment company Arix Bioscience plc, of the Oxford based Drug Discovery Company e-Therapeutics plc and of Respiratory Innovation Wales Ltd. Professor Jones is also a visiting professor at King’s College, London and was appointed to the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health.
EUMCA Team

Sita Schubert
General Secretary
Attorney at Law – Life Science and Economy Compliance, HealthCare
Founding Member of Healthcare Business Network “Female Leaders in Healthcare”

Keith Williams
Deputy General Secretary
More than 20 years Operational experience: General Management, Commercial, Sales & Marketing with Blue Chip companies (GSK, MSD, LEO, Ledian Biosciences). Over 13 years experience managing and selling rare disease products and unlicensed medicines in UK, Ireland, Nords and EU.
Established Ledian Biosciences (EU rare disease business) in the UK
Former Director and Co-Founder of LogixX Pharma

Jeremy Morais
Medical Director
An experienced, GMC registered pharmaceutical physician with a successful track record working with rare disease, generics and innovator medicines in a broad range of therapy areas.
Extensive experience working in clinical development, medical affairs, pharmacovigilance, medical information and compliance functions and managing head office and field-based teams in medical.
An ABPI final signatory for over 16 years with an excellent track record of managing successful national, regional and global multidisciplinary teams. Involved in planning and executing clinical trial and medical affairs strategies as well as change management processes to meet organisational requirements.

Gudrun Köhler
Treasurer

Penny Lukats
Communications Director

Lisa Williams
Marketing Communications

Lucy Hand
Marketing Communications

The voice for ethical European manufacturers and suppliers of pharmaceutical grade cannabis
The European Medicinal Cannabis Association

The voice for ethical European manufacturers and suppliers of pharmaceutical grade cannabis

EUMCA Founding members

- Bundesverband der Pharmazeutischen Industrie e.V.
- Ethical Medicines Industry Group
- Medcann World Forum - Malta
- CANNAFLOS
- IQANNA
- MATERIA
- TILRAY
- PANAXIA Pharmaceutical Industries
- COMM-OP EUROPE

www.eumca.org
Our Mission
In order to improve the life and health outcomes of patients across Europe, the EUMCA facilitates the development of national government healthcare policies that advocate for the ethical prescription of pharmaceutical-grade medicinal cannabis, and advance patient access to treatments.

Our vision
To advance patient access to medicinal cannabis treatments, and improve the health outcomes of patients across Europe.
The EUMCA is the authoritative voice for the medicinal cannabis industry, representing ethical European manufacturers and suppliers of pharmaceutical-grade medicinal cannabis products, vertical associations and patient advocacy groups. We also represent the interests of Pharmaceutical and healthcare organisations who have an interest in establishing their presence in this fast-evolving industry.

Our primary goal is to create a standardised and harmonised regulatory prescribing framework to which all EU countries can confidently ascribe.

We campaign to ensure that the medicinal cannabis industry, those who conform with acknowledged scientific standards of quality, safety and efficacy, are represented at the highest level – governments and regulators throughout the European Union.

By engaging with European governments and regulators, we can create credible, lasting partnerships and coherent policy frameworks, encompassing important areas including: Research & Development; Manufacturing; Regulatory; Patient Access & Reimbursement.
The European Medicinal Cannabis Association

What makes us different

Our Ethics
The EUMCA is the only not-for-profit European medicinal cannabis association, that is both registered and governed by the provisions of the Belgian Code des Sociétés et des Associations, and registered on the European Commission Transparency Registry.

Our Expertise
The EUMCA management team’s aggregated experience in science, pharmaceuticals, medicine, policy and government, uniquely places it to leverage best practice as we drive positive change and innovation in medicinal cannabis prescribing.

Our Vision
To advance patient access to medicinal cannabis treatments and improve the health outcomes of patients across Europe.
Together, we seek a standardised and harmonised regulatory prescribing framework to which all EU countries can confidently ascribe.

Our Mission
To improve the life and health outcomes of patients across Europe, by facilitating the development of national government healthcare policies that advocate for the ethical prescription of pharmaceutical-grade medicinal cannabis, and advance patient access to treatments.

Our Network
The EUMCA is a multi-stakeholder network representing the interests of a wide range of organisations operating in the research and development, production and/or distribution of medical cannabis-based treatments.

Our Values
The EUMCA recognises that this will only be achieved through the creation of a supportive regulatory environment in which producers and manufacturers sign up to good manufacturing practices (GMP) and deliver medicinal cannabis treatments that conform with acknowledged scientific standards of quality, safety and efficacy.
Key pillars

- **Policy**: Collaborating with EU stakeholders to inform the policy debate in order to create a harmonised prescribing framework

- **Research & Development**: Promoting scientific medical research and policy to support the standardised, ethical, and sustainable use of medicinal cannabis

- **Patient Access & Reimbursement**: Working with national reimbursement institutions, to improve patient access to medical cannabis-based treatments

- **Medical Education**: Providing evidence-based knowledge and learning on medicinal cannabis to healthcare professionals and patients

- **Legal & Compliance**: Developing and reviewing policies and procedures which raise awareness of legal compliance, ethics and changes in regulation

- **Regulatory & Quality**: Providing members with counsel and guidance on regulatory affairs

- **Business Development**: Delivering networking opportunities for members focused on building their business through M&A, licensing, partnering and novel in-market strategies
Why join the European Medicinal Cannabis Association?

The European Medicinal Cannabis Association (EUMCA) is the only not-for-profit European medicinal cannabis association, that is both registered and governed by the provisions of the Belgian Code des Sociétés et des Associations and registered on the European Commission Transparency Registry.

Our members consist of a multi-stakeholder network, all of which promote advancing patient access through the production of cannabis treatments that conform with acknowledged scientific standards of quality, safety and efficacy.

EUMCA members include:

• Scientific research and development
• Cultivation, production, manufacturer and distribution
• Patient advocacy and charities
• Regulation and Policy

If you are interested in joining the EUMCA please contact us on info@eumca.org or complete an Application form. We offer both Full and Affiliate Membership.
Member representation

• The EUMCA is a multi-stakeholder network representing the interests of a wide range of organisations operating in the research and development, production and/or distribution of medical cannabis-based treatments

• We represent the collective voice of our members, generating policies with the aim to create a positive environment for the use of medicinal cannabis in Europe

• As a membership organisation, we work with our member companies and the wider medicinal cannabis community, to develop and present policies to the European Union and their national member state governments, reimbursement organisations and regulatory authorities
How we support our Full members

- EUMCA News Flash – Regular updates on current topics/issues related to medicinal cannabis
- Proactive support for members on upcoming media and industry specific issues related to their business
- Quarterly Government affairs reports
- Access and input to the development of briefing papers and policy positions
- Invite to our EUMCA Annual Meeting and EUMCA Conference
- Feedback from meetings and discussions with all key stakeholders in the EU (national governments, regulatory agencies, payers, patient organisations and Scientific leaders)

Access to expertise

- Full members receive access to expertise, knowledge and resources within the EUMCA on key matters affecting the medicinal cannabis industry.
- Full members may be involved with external activities along with their EUMCA associates, such as meeting politicians, advisers, stakeholders, and patient organisations within Europe
- Full members can engage directly with the EUMCA team and other company members to feed back and help shape policy on a wide range of areas

Access to Expert Networks and Specialist Working Group meetings

- We use project working groups and expert networks to cover most industry hot topics. These groups are made up of member companies with special interest and expertise in these areas. This means that we can react quickly to any new issues as they arise. It is these expert networks which help us to draw up responses to consultations and respond quickly to industry opportunities and challenges
- The EUMCA runs the specialist groups meetings at venues agreed by those members attending. Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking
- Examples of Networks and groups include: Research & Development, Legal/Compliance, Regulatory & Quality, Patient Access & Reimbursement, Medical Education and Business Development

Company visits

Our membership team will arrange a company visit for new and existing members with our Senior Leadership Team, who will tailor their visit to your specific requirements and discuss key priorities and focus of the EUMCA in relation to your business.
The European Medicinal Cannabis Association

The voice for ethical European manufacturers
and suppliers of pharmaceutical grade cannabis

Membership Fees – Full Members

<table>
<thead>
<tr>
<th>Annual Turnover (EUR)</th>
<th>%</th>
<th>Annual Membership Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 1 Million</td>
<td>basic</td>
<td>2,000 EUR</td>
</tr>
<tr>
<td>from 1 Million</td>
<td>0.40 %</td>
<td>4,000 EUR</td>
</tr>
<tr>
<td>from 2 Million</td>
<td>0.35 %</td>
<td>7,000 EUR</td>
</tr>
<tr>
<td>from 3 Million</td>
<td>0.35 %</td>
<td>10,500 EUR</td>
</tr>
<tr>
<td>from 5 Million</td>
<td>0.35 %</td>
<td>17,500 EUR</td>
</tr>
<tr>
<td>from 7 Million</td>
<td>0.34 %</td>
<td>23,800 EUR</td>
</tr>
<tr>
<td>from 10 Million</td>
<td>0.32 %</td>
<td>32,000 EUR</td>
</tr>
<tr>
<td>from 15 Million</td>
<td>0.28 %</td>
<td>42,000 EUR</td>
</tr>
<tr>
<td>from 25 Million</td>
<td>0.24 %</td>
<td>60,000 EUR</td>
</tr>
<tr>
<td>from 50 Million</td>
<td>0.17 %</td>
<td>85,000 EUR</td>
</tr>
<tr>
<td>from 100 Million</td>
<td>0.12 %</td>
<td>120,000 EUR</td>
</tr>
</tbody>
</table>

The annual membership fees for Full members. The annual turnover is defined by the relevant EU provisions (Recommendation 2003/361/EC).

Patient or Industry Organisations/Associations are not charged a Membership Fee.

Please contact us to discuss Affiliate Membership
How we support our Affiliate members

Affiliate membership is open to organisations with an interest in the medicinal cannabis industry that operate in Europe

- EUMCA News Flash – Regular updates on current topics/issues related to medicinal cannabis
- Quarterly Government affairs reports
- Receive invitations to selective events and specialist working groups on topical issues, providing excellent opportunities for networking

Feedback from meetings and discussions with all key stakeholders in the EU (national governments, regulatory agencies, payers, patient organisations and Scientific leaders)

Access to Expert Networks and Specialist Working Group meetings

- We use project working groups and expert networks to cover most industry hot topics. These groups are made up of member companies with special interest and expertize in these areas. This means that we can react quickly to any new issues as they arise. It is these expert networks which help us to draw up responses to consultations and respond quickly to industry opportunities and challenges
- The EUMCA runs the specialist group meetings at venues agreed by those members attending. Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking
- Examples of Networks and groups include: Research & Development, Legal/Compliance, Regulatory & Quality, Patient Access & Reimbursement, Medical Education and Business Development
- Affiliate members have the opportunity to apply for membership of working groups according to the groups’ terms of engagement
- Affiliate members receive invitations to selective events designed to update members on topical issues, providing excellent opportunities for networking and sharing members’ views
How to apply

Before applying for EUMCA membership you should have read the Membership Policy and Code of Conduct.

To apply for Full membership, please complete and return the Application Form. All applications for membership of the EUMCA are reviewed and approved by the EUMCA Executive Board.

Please contact membership services for more details on +32 233 90 281 or email info@eumca.org.